All News

podcast logo

RheumNow Podcast – Back Talk Listener Questions (12.04.20)

Jack Cush, MD

Dr Jack Cush takes questions from RheumNow listeners

Read Article
pregnant-776506__180.jpg

PIANO Study - Safety of Biologics in Pregnancy

Jack Cush, MD

The results of the long awaited PIANO study have been reported in the journal Gastroenterology, showing that pregnant women with IBD may safely receive biologic or thiopurine therapy throughout the pregnancy without substantial added risk to the unborn or mother.

Read Article
cost.healthcare.jpg

Colchicine Approval Took a Huge Toll on CMS

Colchicine, the old gout drug often cited as a cheap anti-inflammatory, hasn't been such a good deal since FDA approval, a study in JAMA Internal Medicine showed.

Read Article
pills-384846_640%20%281%29.jpg

The tantalising prospect of glucocorticoid-free treatments for systemic vasculitis

Richard Conway, MBBChBAO, PhD

Glucocorticoids are a highly effective treatment in systemic vasculitis but are also a significant cause of long-term harm in the form of treatment related adverse events.

Read Article
gout.podagra.jpg

Pegloticase in Severe Refractory Gout

Olga Petryna, MD

Listen as Dr. Petryna reviews abstracts #0683 (Pharmacokinetics of Pegloticase and Methotrexate Polyglutamate(s) in Patients with Uncontrolled Gout Receiving Pegloticase and Co-treatment of Methotrexate) and #0677 (A Multicenter, Efficacy and Safety Study of Methotrexate to Increase Response Rates in Patients with Uncontrolled GOut Receiving Pegloticase (MIRROR): 12-Month Results of an Open-Label Study) from the 2020 ACR meeting. 

Read Article
Lknee.OA_.jpg

What’s new in knee osteoarthritis that matters?

Janet Pope, MD, MPH, FRCPC

Are intra-articular steroid injections effective in symptomatic knee OA? Do they accelerate cartilage loss? Does weight less actually help? Do we have DMARDs for knee OA? Insights from 2020 ACR Convergence.

Read Article
podcast logo

RheumNow Podcast – ACR 2020 Epilogue (11.20.20)

Jack Cush, MD

Dr. Jack Cush reviews a few more ACR 2020 abstracts and presents a new plan to learn or take in ACR20 content.

Read Article
Dr. Ruderman ( @JointMD) discusses a new pathway - the use of deucravacitinib - to treat psoriatic arthritis at #ACR20. https://t.co/1uz47jKVPv https://t.co/1I5B14w9Ox

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @bella_mehta :Anakinra in #Stills disease - Dbl blind, placebo controlled RCT in Stills disease total 12pts, 6 placebo, 6 Rx grp. All pts reached ACR70 at wk 2 without fever and sustained it at 12 weeks. 5/6 reached ACR90 ABS#1633 https://t.co/CCL6GONnvX https://t.co/KaoXBj3Azp

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway : Dr Benard reports an SLR and meta-analysis of 27 studies comparing 2 rituximab regimes in AAV. 375mg x4 and 1000mg x2 equivalent. Remission in 91% vs 85%. Similar adverse event rates @rheumnow #ACR20 Abstr#2048 https://t.co/6fQNzqsvby

Links:

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recommendations for RA: MTX monotherapy conditionally rec over csDMARD dual or triple Rx, MTX+TNFi @RheumNow https://t.co/HUucJOgQgN https://t.co/xJB2zU1y2U

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: Use MTX, starting oral but remember MTX tricks to maximize success. Folic acid, split dosing, SubQ all keys per Dr. O'Dell to maximize @RheumNow. https://t.co/OEAGi0bSZH https://t.co/aHsHF1Vm4l

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @ejdein1 : Draft #ACR20 Rx Recs for RA: MTX is conditionally recommended with NORMAL LFTs and no advanced fibrosis. Role of HCQ for NALFD has been suggested at ACR, but not enough for mod-high disease activity @RheumNow. https://t.co/XswkhT1f66 https://t.co/bdngrnY9hc

Links:

Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @doctorRBC : Upadacitinib vs. Adalimumab vs. PBO in PsA Phase 3 RCT ⬇️MSK symptoms, PsO, function, pain, fatigue, rads progression in UPA *⃣UPA15 non-inferior to ADA for ACR20, UPA30 superior *⃣Similar VTE in all arms #ACR20 Abs#2026 https://t.co/n5wcKK1juC
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets FAST trial (Plenary) showed opposite of CAREs study. Febuxostat vs PBO in 6128 Gout pts, showed little dropout (~6%) in a 4 year study. Febuxostat (mean 81mg) had similar, flare rates, MACE/cardiac endpoints and CV death vs allopurinol #ACR20 Abstr#L08 https://t.co/EUXQqy3VuI
Dr. John Cush RheumNow ( View Tweet)
#BestACR20Tweets RT @RichardPAConway :Dr MacDonald presents Febuxostat versus Allopurinol Streamlined Trial. 6128 patients. HR 0·89 [95% CI 0·75-1·06] for cardiovas. events in febuxostat vs allopurinol. Mortality 7.2% vs 8.6%. Reassuring re cardiovascular safety of febuxostat

Dr. John Cush RheumNow ( View Tweet)

#BestACR20Tweets "RT @DrMiniDey : RITAZAREM trial long-term f/u -RTX vs AZA after RTX-induced remission in ANCA -RTX superior to AZA to prevent relapse -Relapse common regardless of therapy; high-dose RTX not effective beyond treatment period Abs#2052 https://t.co/cKV7qM77og

Links:

Dr. John Cush RheumNow ( View Tweet)

New video! Risk of HCQ Retinopathy: Dr. Kathryn Dao ( @KDAO2011) #ACR20 https://t.co/7BCVvMOm0T https://t.co/DOW91SSi2u

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr. Janet Pope ( @Janetbirdope) reviews abstract #1001 presented at #ACR20 on risk of skin cancer with methotrexate. https://t.co/N0JelI6K5p https://t.co/n07HoO5j3y

Links:

Dr. John Cush RheumNow ( View Tweet)
What is the SEAMless transition from combination Etanercept to Methotrexate? with Dr. Jonathan Kay #ACR20 https://t.co/58raeaE8Mr https://t.co/FUIidcoy4I

Links:

Dr. John Cush RheumNow ( View Tweet)
How well do you know this week's rheumatology news?
Take the rheumIQ quiz
Take the RheumIQ Quiz

×